About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Conjugated Drugs (XDCs) in Oncology Directory - Track 2,500+ Drugs, 1,200+ Companies, and 521 Deals - ResearchAndMarkets.com

The "Unlocking Opportunity: Dominate the Market of Conjugated Drugs (XDCs) in Oncology with Confidence" directory has been added to ResearchAndMarkets.com's offering.

The world of conjugated drugs (XDCs) is transforming cancer treatment, unlocking new levels of precision, conditional activation, and therapeutic potential. However, with rapid advancements, fierce competition, and an ever-expanding pipeline, staying ahead requires more than just insights - it demands up-to-date intelligence, strategic foresight, and data-driven decision-making.

In 2024/25 alone, the oncology pipeline saw a surge of innovation, with 436 new conjugated drugs, over 972 drugs with events, and 10,642 total events spanning 2,505 total drug programs - a clear signal of the accelerating pace and complexity in this space.

Introducing the Conjugated Drugs (XDCs) in Oncology Analytical Tool - your comprehensive solution to navigate this dynamic field, track emerging trends, and capitalize on groundbreaking opportunities.

The Ultimate Tool for Exploring What Makes This Field So Exciting

  • XDCs represent a versatile and rapidly evolving class of cancer therapeutics, with at least seven distinct formats - Antibody-Drug Conjugates (ADCs), Peptide-Drug Conjugates (PDCs), Small Molecule-Drug Conjugates (SMDCs), Radioimmunoconjugates (RDCs), Oligonucleotide-Drug Conjugates (ODCs), Nanoparticle-Drug Conjugates, and Enzyme-Drug Conjugates - making this a highly dynamic space to watch as it reshapes the landscape of precision oncology.
  • XDC payloads are among the most potent and diverse agents in oncology, including microtubule inhibitors, DNA-damaging agents, topoisomerase inhibitors, radioactive isotopes, immune- and gene modulators - each carefully selected and engineered to maximize tumor killing while minimizing systemic exposure, making payload innovation a critical driver of therapeutic impact and differentiation in the XDC space.
  • Linker technology is the molecular lynchpin of XDC performance, enabling precise control over payload release through innovations like cleavable (pH-sensitive, enzyme-sensitive) and non-cleavable linkers. The choice of linker directly impacts stability, pharmacokinetics, and tumor selectivity, making it a strategic lever in optimizing safety, efficacy, and therapeutic index across XDC platforms.
  • Conditional activation strategies add a powerful layer of precision to XDCs, enabling payload release specifically in the tumor microenvironment through triggers such as low pH, tumor-associated enzymes, hypoxia, or redox gradients. This tumor-selective activation enhances therapeutic index by minimizing off-target effects and represents a next-generation approach to smarter, safer drug delivery.
  • The emergence of bi- and multispecific ADCs marks a new era in targeted therapy, enabling simultaneous engagement of multiple tumor antigens or immune effector pathways. This approach enhances tumor selectivity, overcomes antigen heterogeneity, and opens new opportunities for dual payload delivery or immune system modulation, making it a frontier of innovation in the XDC landscape.

The impact? A rapidly growing clinical pipeline, breakthrough FDA approvals, and a surge in investment opportunities - making the XDC field one of the most exciting frontiers in oncology today.

With the Conjugated Drugs in Oncology Analytical Tool you will:

  • Track the Competitive Landscape - monitor active organizations, new drugs, targets, and technologies
  • Accelerate Licensing & Partnerships - access top biotech developers, BD&L contacts, and academic projects
  • Power High-Impact Reports & Presentations - fuel data-driven decisions with near real-time market intelligence - all exportable in ready-made graphs and tables.
  • Engage Key Opinion Leaders (KOLs) - connect with clinical and scientific experts shaping the field.
  • Find the Right Investors - tap into a network of oncology-focused funding partners.
  • Stay Ahead of Industry Events - analyze data from top global oncology conferences (AACR, ASCO, ESMO, ASH, and more)

Your Conjugated Drugs (XDCs) in Oncology Analytical Tool is never out of date thanks to continuous updates and monthly email alerts highlighting the latest developments in the field.

You will have thousands of drugs, targets, companies, clinical trials, deals and much more at your fingertips. See below for a breakdown of near-real-time coverage.

Support & Inspiration at Your Fingertips

Leverage expertise as your virtual business development team - ready when you are. The 24/7 support ensures help is always available, while the rich library of How-to Training Videos empowers you with proven best practices. From competitive pipeline analysis to real-world case studies submitted by fellow users, you'll find actionable insights designed to elevate your work.

Secure Your Access to Unrivaled Intelligence for Strategic Decision-Making in Oncology Drug Development

This tool is powered by an award-winning, artificial intelligence (AI) enhanced intelligence platform with over 25 years of expertise in oncology, delivering uniquely comprehensive business, competitive and clinical intelligence across all stages of oncology drug development.

For business development and search & evaluation, it provides unmatched visibility into the global oncology landscape - spanning technologies, targets, start-ups to pharma, and academic-commercial opportunities - making it a powerful deal book with integrated licensing contacts and thousands of past deals.

In clinical development, the tool features an industry-leading biomarker intelligence panel of over 3,000 biomarkers and tracks their roles as stratifying, predictive, and pharmacodynamic markers, alongside companion diagnostic initiatives from early stage to approval. Proprietary early success/failure indicators spotlight clinical leaders and laggards, helping you monitor and anticipate shifts in the evolving landscape.

The clinical trial intelligence goes beyond endpoints, capturing dosage details, resistance mechanisms, adverse events, food effects, trial phase and status progression, first-in-human (FIH) studies, tumor stage/grade, and line of therapy (LoT) - offering a complete view of the trial landscape.

The publisher simplifies the complexity of combination therapy development, breaking down targets, drug modalities, indications, and trial stages to create a map of evolving strategies for fast, strategic decision-making.

Finally, the publisher integrates Real-World Evidence (RWE) with multi-point analytics tailored to any development stage. Whether segmented by drug modality, co-medication profiles, or biomarker clusters, the tool enables deep, contextual insights - driving faster, smarter, and evidence-based decisions in oncology research and development.

Coverage Breakdown from your Conjugated Drugs (XDCs) in the Oncology Analytical Tool

Competitor Overview

  • Organizations Monitored: 1,200+
  • Organization Types:
  • Corporate: 1,061
  • Private: 606
  • Public: 352
  • Academic: 114
  • Startup: 115
  • Cancer Ctr/Hospital: 40
  • Big Pharma/Biotech: 36

Top 5 Drug Developers:

  • Pfizer (incl Seagen)
  • AstraZeneca
  • AbbVie
  • Immunomedics
  • Hangzhou DAC Biotech

Top 5 Nations:

  • USA
  • China
  • UK
  • Canada
  • South Korea

Pipeline

  • Total No Drugs: 2,500+
  • Discovery: 390+
  • Preclinical: 1370+
  • Phase 1: 370+
  • Phase 2: 230+
  • Phase 3: 83
  • Pre-registration: 7
  • Marketed: 33
  • Target: 478
  • Tumor Types: 215
  • Clinical Trials: 2,426
  • Clinical Biomarkers: 580
  • Drugs in Combination Therapies: 241

Deals & Alliances

  • No. Deals (Last 5 Years): 521
  • BD&L Contacts: >2,400
  • World-Wide Academic Commercial Opportunity Projects: 53

Funding & Investors

  • Funding (Last 5 Years): >1,300
  • Top Investors: 251

For more information about this directory visit https://www.researchandmarkets.com/r/qlg05t

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.